Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Moumi Mondal headshot

Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach

by Moumi Mondal

TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.

Zacks Equity Research

Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?

by Zacks Equity Research

ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.

Zacks Equity Research

Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?

by Zacks Equity Research

Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.

Ekta Bagri headshot

3 Top Genomics Stocks to Add to Your Portfolio in 2025

by Ekta Bagri

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

Zacks Equity Research

Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software

by Zacks Equity Research

ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.

Zacks Equity Research

Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends

by Zacks Equity Research

Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Equity Research

Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips

by Zacks Equity Research

ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 1.04% and 0.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.